<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457860</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-8015-1002</org_study_id>
    <nct_id>NCT00457860</nct_id>
    <nct_alias>NCT00453284</nct_alias>
  </id_info>
  <brief_title>Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease</brief_title>
  <official_title>A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge Antibody Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cambridge Antibody Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal&#xD;
      cells. This may be an effective treatment for chronic lymphocytic leukemia (CLL),&#xD;
      prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL that has not responded to&#xD;
      chemotherapy, surgery or radiation therapy.&#xD;
&#xD;
      PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015&#xD;
      immunotoxin in treating patients who have chronic lymphocytic leukemia, prolymphocytic&#xD;
      leukemia or small lymphocytic lymphoma that has not responded to treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients receive CAT-8015 IV over 30 minutes on days 1, 3, and 5 followed by rest.&#xD;
      Treatment repeats every 4 weeks for up to a total of 10 courses in the absence of dose&#xD;
      limiting toxicity, complete response or disease progression. Patients are followed at 1, 3,&#xD;
      6,12,15,18, 21, 24 months following the start of the last treatment cycle.&#xD;
&#xD;
      Cohorts of 3-6 patients each will receive escalating doses of recombinant CAT-8015 until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose proceeding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is&#xD;
      determined, between16 to 25 new patients will be added to the MTD cohort depending on how&#xD;
      well the CAT-8015 is tolerated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the maximum dose that can be safely administered to a patient</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the toxicity profile of CAT-8015</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Study the clinical pharmacology of CAT-8015</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Observe anti-tumor activity, if any</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the potential of CAT-8015 to induce antibodies</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Investigate the potential of biomarkers to predict any therapeutic or toxic response</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotoxin therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAT-8015 immunotoxin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biological therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Confirmed diagnosis of B-cell leukemia (CLL, PLL or SLL)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Patients with chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL)&#xD;
             are eligible if they have failed 2 or more prior courses of standard chemotherapy&#xD;
             and/or biologic therapy (e.g. Rituxan) and if treatment for progressive disease is&#xD;
             medically indicated. Patients with prolymphocytic leukemia (PLL) will be eligible if&#xD;
             they have failed at least one prior standard chemotherapeutic regimen. Medical&#xD;
             indications for treatment include progressive disease-related symptoms, progressive&#xD;
             cytopenias due to marrow involvement, progressive or painful splenomegaly or&#xD;
             adenopathy, rapidly increasing lymphocytosis, autoimmune hemolytic anemia or&#xD;
             thrombocytopenia and increased frequency of infections.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Life expectancy of greater than 6 months, as assessed by the principal investigator&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Patients with other cancers who meet eligibility criteria and have had less than 5&#xD;
             years of disease-free survival will be considered on a case-by-case basis&#xD;
&#xD;
          -  Ability to understand and sign informed consent&#xD;
&#xD;
          -  Female and male patients agree to use an approved method of contraception during the&#xD;
             study&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Documented and ongoing central nervous system involvement with their malignant disease&#xD;
             (history of CNS involvement is not an exclusion criterion)&#xD;
&#xD;
          -  History of bone marrow transplant&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Patients whose plasma contains either a significant level of antibody to CAT-8015 as&#xD;
             measured by ELISA, or antibody that neutralizes the binding of CAT-8015 to CD22 as&#xD;
             measured by a competition ELISA.&#xD;
&#xD;
          -  HIV positive serology (due to increased risk of severe infection and unknown&#xD;
             interaction of CAT-8015 with antiretroviral drugs)&#xD;
&#xD;
          -  Hepatitis B surface antigen positive&#xD;
&#xD;
          -  Uncontrolled, symptomatic, intercurrent illness including but not limited to:&#xD;
             infections requiring systemic antibiotics, congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would&#xD;
             limit compliance with study requirements&#xD;
&#xD;
        Hepatic function: serum transaminases (either ALT or AST) or direct bilirubin:&#xD;
&#xD;
          -  ≥ Grade 2, unless bilirun is due to Gilbert's disease&#xD;
&#xD;
        Renal function: serum creatinine clearance ≤60mL/min as estimated by Cockroft-Gault formula&#xD;
&#xD;
        Hematologic function:&#xD;
&#xD;
          -  The ANC &lt;1000/cmm, or platelet count &lt;50,000/cmm, if these cytopenias are not judged&#xD;
             by the investigator to be due to underlying disease (i.e. potentially reversible with&#xD;
             anti-neoplastic therapy)&#xD;
&#xD;
          -  Baseline coagulopathy &gt; grade 3 unless due to anticoagulant therapy&#xD;
&#xD;
          -  A patient will not be excluded because of pancytopenia ≥ Grade 3, or erythropoietin&#xD;
             dependence, if it is due to disease, based on the results of bone marrow studies&#xD;
&#xD;
        Pulmonary function:&#xD;
&#xD;
          -  Patients with &lt; 50% of predicted forced expiratory volume (FEV1) or &lt;50% of predicted&#xD;
             diffusing capacity for carbon monoxide (DLCO), corrected for hemoglobin concentration&#xD;
             and alveolar volume. Note: Patients with no prior history of pulmonary illness are not&#xD;
             required to have PFTs. FEV1 will be assessed following bronchodilator therapy.&#xD;
&#xD;
        Recent prior therapy:&#xD;
&#xD;
          -  Cytotoxic chemotherapy, corticosteriods (except stable doses of prednisone), whole&#xD;
             body electron beam radiation therapy, hormonal, biologic or other systemic therapy or&#xD;
             investigational therapy of the malignancy for 3 weeks prior to entry into the trial&#xD;
&#xD;
          -  Less than or equal to &lt; 3 months prior monoclonal antibody therapy (i.e. rituximab)&#xD;
&#xD;
          -  Patients who have received or are receiving radiation therapy less than 3 weeks prior&#xD;
             to study entry will be not be excluded providing the volume of bone marrow treated is&#xD;
             less than 10% and also the patient has measurable disease outside the radiation port&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tower Hematology Oncology Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Fuerst, RN, MS</last_name>
      <phone>310-285-7269</phone>
    </contact>
    <investigator>
      <last_name>Peter Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Cangany, RN, CCRP</last_name>
      <phone>317-278-4694</phone>
    </contact>
    <investigator>
      <last_name>Larry Cripe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Warren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NCI Clinical Trials Referral Office</last_name>
      <phone>888-624-1937</phone>
    </contact>
    <investigator>
      <last_name>Robert J Kreitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Hemtologii Uniwersytetu Medycznego (Medical University of Lodz)</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Krzysztof Jamoziak, MD</last_name>
      <phone>00 48 42 689 5191</phone>
    </contact>
    <investigator>
      <last_name>Tadeusz Robak, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, Wilson WH, Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005 Sep 20;23(27):6719-29. Epub 2005 Aug 1.</citation>
    <PMID>16061911</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 5, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2007</study_first_posted>
  <last_update_submitted>April 16, 2007</last_update_submitted>
  <last_update_submitted_qc>April 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2007</last_update_posted>
  <keyword>CLL</keyword>
  <keyword>PLL</keyword>
  <keyword>SLL</keyword>
  <keyword>Relapse</keyword>
  <keyword>Refractory</keyword>
  <keyword>immunotoxin</keyword>
  <keyword>HA22</keyword>
  <keyword>CAT-8015</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunotoxin HA22</mesh_term>
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

